Hyderabad, Telangana – Health authorities in Telangana have issued a ‘stop use notice’ for a children’s medicine after discovering it was contaminated with Ethylene Glycol, a highly toxic chemical. The directive affects all batches of the concerning product and is a significant step towards safeguarding public health, particularly amongst vulnerable pediatric populations.
The alert was triggered following reports of adverse health effects in children who consumed the medication. Preliminary investigations revealed the presence of Ethylene Glycol, a substance commonly used in antifreeze and known to cause severe kidney damage, neurological problems, and even death if ingested. The specific medicine and manufacturer details have been widely reported through The Hindu and other local news outlets.
Public Health Response
The Telangana State Drugs Control Administration (TSDCA) has initiated a thorough investigation into the source of the contamination. This includes scrutinizing the manufacturing processes, raw material suppliers, and quality control measures employed by the pharmaceutical company. Authorities are working to trace and recall all potentially affected batches from pharmacies and hospitals across the state.
Drug inspectors have been dispatched to collect samples for further laboratory analysis and to ensure compliance with the ‘stop use notice’. The TSDCA has also advised healthcare professionals to remain vigilant and report any suspected cases of Ethylene Glycol poisoning immediately. A state-wide alert has been circulated to medical facilities, requesting them to check their stocks and quarantine the affected product.
Parents and caregivers have been urged not to administer the identified medication to their children and to seek immediate medical attention if a child has already taken it and exhibits symptoms such as drowsiness, vomiting, abdominal pain, or difficulty in breathing. The health department has established a helpline to address public concerns and provide guidance.
This incident raises critical questions regarding pharmaceutical quality control and regulatory oversight in the state. Officials have assured the public that stringent measures will be taken to prevent similar occurrences in the future, including increased inspections of manufacturing facilities and tighter control over the import of raw materials. The severity of the potential health consequences linked to Ethylene Glycol ingestion necessitates a swift and comprehensive response. The recall process is being overseen to minimize public exposure.
The manufacturer has been contacted for comment and is cooperating with the investigation. However, the company has not yet released an official statement regarding the contamination. Further updates will be provided as the investigation progresses and more information becomes available. The primary focus remains on identifying and assisting children who may have been affected by the contaminated medicine, ensuring access to appropriate medical care and support.
Image Source: Google | Image Credit: Respective Owner
